Testing effectiveness (Phase 2)Study completedNCT01522469
What this trial is testing
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
Who this might be right for
Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Arog Pharmaceuticals, Inc. 14